Track RNA and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Create a free account to build watchlists, compare peers, and value any stock.
No credit card required
RNA - Atrium Therapeutics, Inc. Common Stock (RNA) has a shares outstanding of 137.71M, up 7.2% over the past year.
Shares Outstanding
137.71M
Dilution %
+160.53%
Annual Change
+7.17%
| Year | Shares | Change |
|---|---|---|
| 2025 | 137.71M | +7.17% |
| 2024 | 128.50M | +68.96% |
| 2023 | 76.05M | +32.74% |
| 2022 | 57.30M | +142.70% |
| 2021 | 23.61M | -36.97% |
| 2020 | 37.45M | +81.10% |
| 2019 | 20.68M | -60.87% |
| 2014 | 52.86M | +0.00% |
| 2013 | 52.86M | - |
| Quarter | Shares | Change |
|---|---|---|
| Q1 2026 | - | - |
| Q4 2025 | 137.71M | -0.13% |
| Q3 2025 | 137.90M | +6.38% |
| Q2 2025 | 129.62M | +0.30% |
| Q1 2025 | 129.23M | +0.57% |
| Q4 2024 | 128.50M | +4.15% |
| Q3 2024 | 123.38M | +15.38% |
| Q2 2024 | 106.93M | +22.61% |
| Q1 2024 | 87.21M | +14.67% |
| Q4 2023 | 76.05M | +2.64% |
| Q3 2023 | 74.10M | +3.79% |
| Q2 2023 | 71.39M | +1.36% |
| Q1 2023 | 70.43M | +22.93% |
| Q4 2022 | 57.30M | +7.97% |
| Q3 2022 | 53.07M | +6.29% |
| Q2 2022 | 49.93M | +3.48% |
| Q1 2022 | 48.25M | +104.37% |
| Q4 2021 | 23.61M | -45.44% |
| Q3 2021 | 43.27M | +15.12% |
| Q2 2021 | 37.58M | +0.17% |
| Q1 2021 | 37.52M | +0.18% |
| Q4 2020 | 37.45M | +0.09% |
| Q3 2020 | 37.42M | +335.83% |
| Q2 2020 | 8.59M | -72.26% |
| Q1 2020 | 30.95M | +49.65% |
| Q4 2019 | 20.68M | +0.00% |
| Q3 2019 | 20.68M | +0.00% |
| Q2 2019 | 20.68M | +0.00% |
| Q1 2019 | 20.68M | -60.87% |
| Q2 2014 | 52.86M | +0.00% |
| Q1 2014 | 52.86M | +0.00% |
| Q4 2013 | 52.86M | - |
| Q3 2013 | - | - |
| Q2 2013 | - | - |
| Q1 2013 | - | - |
| Q4 2012 | - | - |
| Q3 2012 | - | - |
| Q2 2012 | - | - |
| Q1 2012 | - | - |
Shares outstanding is the total number of a company's shares currently held by all its shareholders. A shrinking share count usually reflects buybacks that raise each remaining share's claim on earnings, while a rising count can signal dilution.